Page 2 - Crohn X27s Disease News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Crohn x27s disease. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Crohn X27s Disease Today - Breaking & Trending Today

Use of Upadacitinib in Treatment of CD

Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib. ....

David Rubin , Miguel Regueiro , Sara Horst , Remo Panaccione , Marla Dubinsky , Crohn X27s Disease , Jak Inhibitors ,

Selecting CD Treatment in Special Scenarios

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations. ....

Remo Panaccione , Sara Horst , Miguel Regueiro , David Rubin , Marla Dubinsky , Crohn X27s Disease , Treatment Selection , Extra Intestinal Manifestations ,

Marla Dubinsky, MD: Using Off-Label Treatments to Address the Unmet Need in Pediatric IBD

Marla Dubinsky, MD, discusses the use of off-label upadacitinib in pediatric IBD patients and the importance of this research due to delays in pediatric drug approvals. ....

Marla Dubinsky , Drug Administration , Mount Sinai Kravis Children , Mount Sinai , Inflammatory Bowel Disease , Ulcerative Colitis , Crohn X27s Disease , Anti Tnf ,

'It's Completely Changed My Practice': Marla Dubinsky, MD, on Intestinal Ultrasound for Crohn's Disease

Marla Dubinsky, MD, discusses the use of segmental intestinal ultrasound to address screen failure associated with the SES-CD in clinical trials and for detecting transmural healing. ....

Marla Dubinsky , Simple Endoscopic Score , Crohn Disease , Crohn Disease Activity Index , Mount Sinai Kravis Children , Inflammatory Bowel Disease , Ulcerative Colitis , Crohn X27s Disease , Simple Endoscopic Score For Crohn X27s Disease , Ses Cd ,

Interchangeability, Adverse Event Considerations for Adalimumab Biosimilars in IBD

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug. ....

Eduardo Redondo Cerezo , Linkedin Eduardo Redondo Cerezo , University Of Grenada , Virgen De Las Nieves University Hospital , Inflammatory Bowel Disease , Ulcerative Colitis , Crohn X27s Disease ,